Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD Source: Eur Respir J 2013; 41: 1042-1050 Year: 2013
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
The interaction between leptin and inflammatory markers in induced sputum in patients with moderate COPD Source: Eur Respir J 2002; 20: Suppl. 38, 404s Year: 2002
To correlate of the NOS1 C/T polymorphism with the activity of proteases and antiproteases in the serum and sputum in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 585s Year: 2006
Differences in biomarkers of systemic inflammation in two phenotypes of COPD patients Source: Annual Congress 2011 - COPD: human studies Year: 2011
Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012
The interrelation between inflammation markers and protease-antiprotease status in blood serum in patients with stable COPD Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007
Alterations in sputum inflammatory markers during exacerbations for COPD patients with different stable state levels Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019
Neutrophil elastase levels in sputum of patients with different airway diseases: COPD, bronchiectasis and asthma Source: Eur Respir J 2002; 20: Suppl. 38, 95s Year: 2002
Some local markers indices of saliva inflammation in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Correlation of HRCT proven inflammatory changes with serum levels of ACE, sIL-2r and calciuria in pulmonary sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Relations between serum lipid levels and inflammatory markers in obese asthma. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Impact of treatment on a number of BALF inflammatory cells and cytokines concentrations in patients with moderate COPD Source: Annual Congress 2008 - COPD: from bench to bedside Year: 2008
Different concentrations of CCL18 in serum and BALF of ILDs: A marker of pulmonary inflammation? Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010
Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021
Increased serum levels of LL37, HMGB1 and S100A9 during exacerbation in COPD patients Source: Eur Respir J 2015; 45: 1482-1485 Year: 2015